Unresectable
13
4
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
IMCgp100 in Advanced Unresectable Melanoma
Cetuximab + Gemox in Biliary Tract Cancer
Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma